MaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board
November 03 2021 - 9:00AM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading
commercial cell-engineering company focused on providing enabling
platform technologies to advance innovative cell-based research as
well as next-generation cell therapeutic discovery, development and
commercialization. The company today announces that its Board of
Directors has appointed Richard Douglas, PhD, as Chair of the
Board. Richard Douglas has been a Board Member since February 2018.
He succeeds J. Stark Thompson, PhD, who previously announced his
decision not to seek re-election. Dr. Thompson will remain as a
consultant to MaxCyte.
“MaxCyte’s ExPERT™ technology and cell
engineering expertise is well-known throughout the industry and I’m
extremely proud to step into the role of Board Chair on the heels
of its first U.S. public offering, which marks a pivotal time in
the Company’s history,” said Dr. Douglas.
Dr. Douglas is a veteran pharmaceutical executive who presently
serves as an adviser at RedSky Partners, Chair of the Board of
Aldeyra Therapeutics, a director of Novavax Inc., and Chair of the
National Advisory Board of Innovation Partnerships at the
University of Michigan. He formerly held the role of Senior Vice
President of Corporate Development and Corporate Officer at Genzyme
Corporation where he led numerous acquisitions, licenses,
financings, joint ventures, and strategic alliances. He had
previously held scientific and corporate development roles at
Integrated Genetics.
“Since bringing his wealth of experience to the board in 2018,
Richard has been a valuable contributor as we sought to list on the
Nasdaq. His new role is a natural transition for him to continue
the strong, impactful leadership that MaxCyte has enjoyed under
Stark’s guidance of the Board since the founding of MaxCyte,”
commented Doug Doerfler, Chief Executive Officer, President
and Founder of MaxCyte. “Stark helped set the foundation
as we built MaxCyte to be the leading enabling platform technology
in cell therapy worldwide. It has been a true honor to work with
him and we thank him for his dedication and perspective.”
“It has been an honor to serve on the MaxCyte board. The
company is well positioned to continue providing its
industry-leading technology to the rapidly expanding cell
therapy development pipeline,” remarked Dr.
Thompson.
About MaxCyte
MaxCyte is a leading commercial cell-engineering
company focused on providing enabling platform technologies to
advance innovative cell-based research as well as next-generation
cell therapeutic discovery, development and commercialization. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation® platform, which facilitates
complex engineering of a wide variety of cells. Our ExPERT™
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: three instruments, the ATx™,
STx™ and GTx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR
AdviserGilmartin GroupDavid Deuchler,
CFA |
+1
415-937-5400 ir@maxcyte.com |
US Media
RelationsLaura MorganSam Brown Healthcare
Communications |
+1
951-333-9110lauramorgan@sambrown.com |
Nominated Adviser and
Joint Corporate BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden |
+44 (0)20 7886 2500 |
UK IR
AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh |
+44 (0)203 709
5700maxcyte@consilium-comms.com |
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024